The aim of the project is to further develop and optimize the OncoCDx companion diagnostic platform through its integration with a dedicated in-house next-generation sequencing (NGS) facility. The project will focus on implementing advanced molecular profiling workflows and integrated bioinformatics tools to enable comprehensive characterization of tumor samples and the identification of predictive biomarkers associated with response to cancer immunotherapy.

The integration of the OncoCDx platform with high-throughput sequencing technologies will significantly enhance the sensitivity, scope, and efficiency of molecular diagnostics while reducing turnaround time for clinically actionable results. This approach will facilitate the translation of genomic insights into clinical decision-making and support physicians in selecting the most appropriate immunotherapeutic strategies for individual patients.

As a result, the project will deliver an advanced companion diagnostic platform enabling the implementation of precision oncology approaches in clinical practice. Ultimately, the project is expected to improve patient stratification, optimize treatment selection, and contribute to better clinical outcomes for cancer patients receiving immunotherapy.

Total project value: 995 200 €

EU funds: 783 360 €